The effect of short-term intensive chemotherapy on reactivation of tuberculosis

Annals of Oncology

Volumn 18, Issue 7, 2007, Pages 1243-1245

  Nair, R ^a   Prabhash, K ^a   Sengar, M ^a   Bakshi, A ^a   Gujral, S ^a   Gupta, S ^a   Parikh, P ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Cyclical chemotherapy; Cytotoxic chemotherapy; Lymphoma treatment; Non Hodgkin's lymphoma; Reactivation; Tuberculosis

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; PLATINUM DERIVATIVE; PREDNISOLONE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; MALE; NONHODGKIN LYMPHOMA; PATIENT ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SHORT COURSE THERAPY; TUBERCULOSIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, NON-HODGKIN; MALE; MESNA; METHYLPREDNISOLONE; MIDDLE AGED; MITOXANTRONE; MYCOBACTERIUM TUBERCULOSIS; PREDNISONE; RETROSPECTIVE STUDIES; TUBERCULOSIS; VINCRISTINE; VIRUS ACTIVATION;

EID: 34547844165     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm107     Document Type: Article

References (15)

1. Cliffton EE, Irani BB. Pulmonary tuberculosis and cancer, NY State J Med 1970; 70: 274-278.
2. Kamboj M, Kent AS. The risk of tuberculosis in patients with cancer. Clin Infect Dis 2006; 42(11): 1592-1595.
3. Feld R, Bodey GP, Groschel D. Mycobacteriosis in patients with malignant disease. Arch Intern Med 1976; 136(1): 67-70.
4. Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease. A review at 201 cases. Cancer 1974; 33(3): 850-858.
5. Diagnostic standards and classification of tuberculosis in adults and children. T1999 [This statement was endorsed by the Council of the Infectious Disease]. Am J Respir Crit Care Med 2000; 161 (4 pt 1): 1376-1395
6. Tuberculosis Research Centre. Trends in the prevalence and incidence of TB in south India. Int J Tuberc Lung Dis; 2001; 5: 142-157.
7. Gopal R, Nair R, Mirchandany K et al. Alternating triple therapy (CHOP-MINE-ESHAP) in large B cell phenotype on Hodgkin's lymphoma. Proc Am Soc Clin Oncol 2001: 20 (Abstr 1160).
8. Dye C, Scheele S, Dolin P et al. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282(7): 677-686.
9. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994; 72(2): 213-220.
10. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva, Switzerland: World Health Organization 2006.
11. Verver S, Warren RM, Beyers N et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis, Am J Respir Crit Care Med 2005; 171(12): 1430-1435.
12. Karachunskii MA, Pivnik AV, Iuldasheva NE. Tuberculosis in patients with hemoblastoses. Probl Tuberk 2002; 12: 24-27.
13. Harakati SE. Tuberculosis in patents with lymphoproliferative disorders: Is it as common as historically stated? Kuwait Med J 2001; 33: 325-328.
14. Kim DK, Lee SW, Yoo CG et al. Clinical characteristics and treatment responses of tuberculosis in patients with malignancy receiving anticancer chemotherapy. Chest 2005; 128(4): 2218-2222.
15. George B, Mathews V, Srivastava V et al. Tuberculosis among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant 2001; 27(9): 973-975.